Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HIV-1 Integrase T218I/S Polymorphisms Do Not Reduce HIV-1 Integrase Inhibitors' Phenotypic Susceptibility.

AIDS research and human retroviruses - 1 Jan 2025

Rodríguez-López Elliott R, López Pablo, Rodríguez Yadira, Sánchez Raphael, Acevedo Van-Sergei, Encarnación Jarline, Tirado Grissell, Ortiz-Sánchez Carmen, Mesplède Thibault, Rivera-Amill Vanessa

Abstract excerpt

The recently Food and Drug Administration (FDA)-approved cabotegravir (CAB) has demonstrated efficacy as an antiretroviral agent for HIV treatment and prevention, becoming an important tool to stop the epidemic in the United States of America (USA). However, the effectiveness of CAB can be compromised by the presence of specific integrase natural polymorphisms, including T97A, L74M, M50I, S119P, and E157Q,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Heterocyclic Compounds, 3-Ring
Share to HIV Integrase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Integrase Inhibitors

Share to Oxazines

Share to Piperazines

Share to Pyridones

Share to Quinolones

Share to Raltegravir Potassium

Source

Open in PubMed Open full text

Identifiers

PMID: 39086253
DOI: 10.1089/AID.2023.0128
PMCID: PMC11807902

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HIV-1 Integrase T218I/S Polymorphisms Do Not Reduce HIV-1 Integrase Inhibitors' Phenotypic Susceptibility.PMID 39086253Read ↗

Genotypic Correlates of Resistance to the HIV-1 Strand Transfer Integrase Inhibitor CabotegravirSemantic proximity Read ↗

Genotypic correlates of resistance to the HIV-1 strand transfer integrase inhibitor cabotegravir.Semantic proximity Read ↗

Antiviral activity of HIV‐1 integrase strand‐transfer inhibitors against mutants with integrase resistance‐associated mutations and their frequency in treatment‐naïve individualsSemantic proximity Read ↗

In-vitro phenotypic susceptibility of HIV-1 'non-B' integrase inhibitors naive clinical isolates to dolutegravir and raltegravir.Semantic proximity Read ↗

Impact of combinations of clinically observed HIV integrase mutations on phenotypic resistance to integrase strand transfer inhibitors (INSTIs): a molecular study.Semantic proximity Read ↗

Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressureSemantic proximity Read ↗

Resistance to HIV Integrase Inhibitors: About R263K and E157Q Mutations.Semantic proximity Read ↗

Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome.Semantic proximity Read ↗

Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profilesSemantic proximity Read ↗

Genotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohort.Semantic proximity Read ↗

Lack of resistance to integrase inhibitors among antiretroviral-naive subjects with primary HIV-1 infection, 2007-2013.Semantic proximity Read ↗

Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.